We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prostate Needle Biopsy Biomarker Predicts Tumor Aggressiveness

By LabMedica International staff writers
Posted on 11 Apr 2016
Print article
Image: Schematic diagram of a transrectal prostate biopsy (Photo courtesy National Cancer Institute).
Image: Schematic diagram of a transrectal prostate biopsy (Photo courtesy National Cancer Institute).
A new study demonstrates the ability to measure and evaluate biomarkers from ribonucleic acid (RNA) expression data obtained from prostate needle biopsies. The data demonstrate a high concordance in the genomic signatures between needle biopsy samples and post-prostatectomy tissue samples.

The study showed that genetic information from prostate needle biopsy may be used to predict tumor aggressiveness and provided preliminary evidence that the Decipher score may be predictive of disease progression following biopsy as well as following prostate surgery and concordance in molecular information between prostate biopsy and surgery samples analyzed.

Scientific collaborators from Cedars Sinai Medical Center (Los Angeles, CA, USA) and other institutions compared analysis of a total of 158 samples from 33 men, including pre-operative needle core biopsies and tissues obtained from radical prostatectomy. The identified 95% of transcriptomic features expressed in surgical samples were expressed in pre-surgery biopsy samples with a high expression correlation. The expression signature pattern yielded by Decipher Biopsy (GenomeDx Biosciences; Vancouver, BC, Canada) showed a high degree of correlation between the two sample types providing strong evidence of the utility of Decipher Biopsy in prostate needle biopsies.

Jeffry Simko, PhD, MD, a Professor of Clinical Pathology, said, “More than 800,000 men undergo prostate biopsy annually in the United States to identify prostate cancer, and this study increases confidence that reliable, quality genomic information can be obtained for those biopsies to better classify patient risk. Genomic biomarkers used by Decipher may help overcome current challenges of tumor heterogeneity and variability in staging of disease. Studies demonstrate that the Decipher score may be predictive of disease progression in diagnostic prostate needle biopsies and warrants a larger, adequately powered study to validate this observation.” The study will be published in the May 2016 issue of Journal of Molecular Diagnostics.

Related Links:

Cedars Sinai Medical Center 
GenomeDx Biosciences 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more